Morgan Stanley Sets Bullish $1,327 Target for Eli Lilly Amid Weight-Loss Dominance

Eli Lilly (NYSE: LLY) continues to see strong support from Wall Street, with Morgan Stanley analyst Terence Flynn reiterating an 'overweight' rating and setting a price target of $1,327. This target represents a potential 52% increase from the stock's current trading price of approximately $870. The bullish outlook is primarily driven by Lilly's leadership in the weight-loss sector. While the company currently trades at a premium valuation of 25.7x forward earnings—significantly higher than the healthcare sector average of 17x—Flynn argues that the growth trajectory justifies the price. Financial projections indicate that the combination of Zepbound and the newly launched oral pill, Foundayo, could generate $31 billion in U.S. sales next year, potentially climbing to $45 billion by 2030. For context, Zepbound recorded worldwide revenues of $13.5 billion in 2025. Despite headwinds, such as CVS Health shifting coverage from Zepbound to Novo Nordisk's Wegovy, Lilly's pipeline remains robust. The company is currently conducting Phase 3 trials for retatrutide, which has shown a mean weight loss of 28.7% in late-stage studies. Additionally, Foundayo is being tested for obstructive sleep apnea and hypertension. If the price target is achieved, Eli Lilly's market capitalization would surpass the $1 trillion threshold, cementing its position as a dominant force in global healthcare and expanding its reach beyond core obesity treatments into oncology and other therapeutic areas.